![]() |
市场调查报告书
商品编码
1442911
放射免疫分析 (RIA) - 全球市场回顾、竞争格局、市场预测 (2030)Radioimmunoassay (RIA) - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球放射免疫分析(RIA)市场规模预计到2023年将达到5.2398亿美元,到2030年将达到6.6031亿美元,2024-2030年预测期间复合年增长率为3.36%。放射免疫分析(RIA)的需求主要是由癌症、传染病等盛行率的增加、流行病和大流行病发生率的增加以及健康意识的提高所驱动。此外,市场预计将受益于该领域众多正在进行的研究活动、医疗保健提供者和研究人员、行业参与者、战略合作伙伴之间的合作等,从而为2024-2030 年预测期内市场的整体增长做出贡献。预计将做出贡献。
放射免疫分析 (RIA) 市场动态
根据International Agency for Research on Cancer进行的一项研究,2020 年全球估计报告了 1,930 万新癌症病例。
根据世界卫生组织(WHO)数据显示,2020年,乳癌226万例,肺癌221万例,大肠直肠癌193万例,摄护腺癌141万例,胃癌109万例。被通报。
癌症发生率的增加需要早期有效的诊断,这可以透过使用放射免疫分析(RIA)来实现。放射免疫分析 (RIA) 已被证明对于大肠直肠癌和胰腺癌等癌症的早期检测极为重要。
此外,根据世界卫生组织 (WHO) (2022) 的数据,2020 年全球约有 3,770 万人感染人类免疫缺乏病毒 (HIV)。根据世界卫生组织2023年数据,2022年全球约有1,000万人罹患结核病。这项估计表明,传染病的盛行率正在上升,增加了对放射免疫分析 (RIA) 进行有效诊断的需求。
然而,放射性材料的使用、对先进实验室设施的需求以及与使用放射免疫分析(RIA)与其他诊断工具和方法相结合相关的限制等多种限制因素可能对整个放射免疫分析(RIA)市场做出了贡献。抑制生长。
放射免疫分析(RIA)市场细分分析
依放射免疫分析 (RIA) 市场的产品类型划分,分析仪预计将在 2023 年占重要的收入占有率。
这可以归因于世界各地传染病和流行病发病率的不断上升,以及肝炎等传染病的高盛行率。
根据世界卫生组织(2022)的数据,2020年全球约有2.41亿人感染疟疾。
根据世界卫生组织(2021)数据,全球每天约有100万人感染性传染病。此外,根据相同数据,估计2020年约有1.29亿例衣原体病例、710万例梅毒病例、8,200万例淋病病例和约1.56亿例滴虫病例。
根据美国疾病管制与预防中心 (2021) 的数据,根据世界卫生组织的估计,2019 年全球约有 2.96 亿人患有B型肝炎,5,800 万人患有C型肝炎。
放射免疫分析仪(RIA)用于识别和检测样本中特定物质的浓度,可以进行多种测试。该分析仪更加可靠,并具有直觉的介面和易于使用的功能。
因此,由于上述因素,分析仪类别预计将显着成长,从而推动整个放射免疫分析(RIA)市场在预测期内的成长。
预计北美将主导整个放射免疫分析 (RIA) 市场。
根据美国疾病管制与预防中心 (2022) 的数据,2019 年美国估计有约 1,189,700 名 13 岁及以上的人感染爱滋病毒。根据美国疾病管制与预防中心 (CDC) (2022) 的数据,2019 年报告了大约 1,752,735 例新癌症病例。
本报告提供了全球放射免疫分析 (RIA) 市场的研究和分析,包括市场规模和预测、驱动因素和挑战以及公司和产品概况。
The Radioimmunoassay (RIA) Market By Product Type (Analyzers And Reagents & Kits), Application (Research And Clinical Diagnostics), End-User (Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing number of people with infectious diseases and increasing research and development activities
The global Radioimmunoassay (RIA) market was valued at USD 523.98 million in 2023, growing at a CAGR of 3.36% during the forecast period from 2024 to 2030 to reach USD 660.31 million by 2030. The demand for radioimmunoassay is primarily being boosted by the growing prevalence of cancer, infectious diseases, and others, rising incidences of epidemics and pandemics coupled with growing awareness of health. Furthermore, the radioimmunoassay market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the radioimmunoassay market during the forecast period from 2024-2030.
Radioimmunoassay (RIA) Market Dynamics:
The study conducted by the International Agency for Research on Cancer mentioned that worldwide, an estimated 19.3 million new cancer cases were reported in 2020.
According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
The increasing burden of cancer necessitates its early and effective diagnosis which can be possible via the usage of radioimmunoassay. Radioimmunoassay is found to be crucial for detecting the early stages of cancer of the colon and pancreas among others.
Also, according to the World Health Organization (WHO) 2022, globally around 37.7 million people suffered from human immunodeficiency virus (HIV) in the year 2020. As per the 2023 data provided by WHO, globally around 10 million people suffered from tuberculosis in 2022. The estimates suggest that the prevalence of infectious diseases is on the rise and will increase the demand for radioimmunoassay for its effective diagnosis.
However, several limitations such as the use of radioactive substances, the need for advanced lab facilities, and others associated with the use of radioimmunoassay coupled with other diagnostic tools and methods may restrict the growth of the overall radioimmunoassay market.
Radioimmunoassay (RIA) Market Segment Analysis:
Radioimmunoassay Market by Product Type (Analyzers and Reagents & Kits), Application (Research and Clinical Diagnostics), End-User (Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type of the radioimmunoassay market, the analyzers, category is expected to amass a significant revenue share in the year 2023.
This can be ascribed to the high incidence of infectious diseases, including hepatitis, and others along with rising incidences of epidemics and pandemics across the globe.
As per the data provided by the WHO 2022, globally around 241 million people suffered from malaria in 2020.
The WHO 2021 data mentioned that, worldwide around 1 million people acquire STDs every day. Also, as per the same source, it was estimated that there were around 129 million cases of chlamydia, 7.1 million cases of syphilis, 82 million cases of gonorrhea, and around 156 million cases of trichomoniasis recorded in the year 2020.
As per Centers for Disease Control and Prevention 2021 based on WHO estimates, in 2019 about 296 million people worldwide were living with hepatitis B, and 58 million people worldwide had hepatitis C.
Radioimmunoassay analyzers can be used to identify and detect the concentration of specific substances in a sample and can perform a variety of tests. The analyzers offer improved reliability, have intuitive interfaces and easy-to-use features.
Therefore, owing to the above-mentioned factors, the analyzers category is expected to register significant growth, thereby driving the growth of the overall radioimmunoassay market during the forecast period.
North America is expected to dominate the overall Radioimmunoassay (RIA) Market:
Among all the regions, North America is estimated to account for the largest share of the Radioimmunoassay market in the year 2023. This can be ascribed to the presence of a large patient pool associated with Sexually transmitted diseases (STSs), cancer, and others, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.
According to the Centers for Disease Control and Prevention 2022, it was estimated that around 1,189,700 people aged 13 and above had HIV in the US in 2019. As per the Centers for Disease Control and Prevention (CDC) (2022), around 1,752,735 new cancer cases were reported in 2019.
As per the American Thyroid Association 2019, around 20 million people in America have some form of thyroid disease, and an estimated 12 percent or more of American people will develop thyroid disease during their lifetime.
Moreover, as per the US Department of Health and Human Services (HHS) press release in the year 2021, the US government had invested USD 650 million in rapid diagnostic testing in the latest action to increase access to tests.
Thus, the above-mentioned factors are likely to propel the growth of the Radioimmunoassay market in the region during the forecast period from 2024-2030.
Radioimmunoassay (RIA) Market Key Players:
Some of the key market players operating in the Radioimmunoassay market include DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and Others.
Key Takeaways from the Radioimmunoassay (RIA) Market Report Study
Target Audience who can be benefited from this Radioimmunoassay (RIA) Market Report Study
Frequently Asked Questions for the Radioimmunoassay (RIA) Market:
Radioimmunoassay is for determining antibody levels by introducing an antigen labeled with a radioisotope and measuring the subsequent radioactivity of the antibody component.
The global Radioimmunoassay (RIA) market was valued at USD 523.98 million in 2023, growing at a CAGR of 3.36% during the forecast period from 2024 to 2030 to reach USD 660.31 million by 2030.
The demand for radioimmunoassay is primarily being boosted by the growing prevalence of cancer, infectious diseases, and others, rising incidences of epidemics and pandemics coupled with growing health awareness. Furthermore, the radioimmunoassay market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the radioimmunoassay market during the forecast period from 2024-2030.
Some of the key market players operating in the radioimmunoassay market include DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and Others.
North America is expected to dominate the overall radioimmunoassay market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient pool associated with Sexually transmitted diseases (STSs), cancer, and others, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.